ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP03

My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis

Tugce Turten Kaymaz

Meeting: ACR Convergence 2025

Keywords: Health Care, pregnancy, quality of life, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (PP01-PP08) Patient Perspectives Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: At the age of 26, the same month I got married, I was diagnosed with Takayasu Arteritis following severe chest and back pain. Hypertension was added to my condition two years later. My treatment varied but included deltacortril, PULSE, methotrexate, infliximab, and tocilizumab. As a result, I had to avoid pregnancy from the beginning of my marriage. Four years after the diagnosis, I experienced pregnant unexpectedly while using tocilizumab. What should have been joyful news became a source of fear and uncertainty for us. After my rheumatologist explained the risks, we decided to continue the pregnancy at 10 weeks. However, at the first perinatologist visit, anomaly was suspected, followed by a trisomy 21 diagnosis, and the pregnancy was terminated at week 16. Five months later, I had a planned pregnancy that ended in miscarriage due to an ectopic pregnancy. Both pregnancies ended in loss. I experienced bleeding, and curettage was done without any anesthesia, increasing my fear of gynecology clinics. After these experiences, my husband and I silently closed the door on having children.

Intervention: During the COVID-19 pandemic, I couldn’t access tocilizumab for six months. At the check-up six months later, my doctor  informed me that my condition was stable enough to go without medication for a period and try for a baby. A month later, I went to the ER with severe groin pain and learned I was pregnant again. What followed were weeks filled with fear: suspicions of ectopic pregnancy, then heterotopic pregnancy, and bleeding. I found myself once again face-to-face with the very fears I had hoped to avoid. Until I found my perinatologist.

Maintenance: I had check-ups every three weeks in the first two trimesters, and every two weeks in the third. The communication and coordination between my rheumatologist and perinatologist were crucial components of my pregnancy care. My anxiety decreased thanks to my doctor’s clear, calming communication without overemphasizing risks. Working from home due to the pandemic also reduced physical stress and allowed me to have a rest-focused, and calm pregnancy. My third pregnancy ended happily with the birth of a healthy baby girl in the 41st week.

Quality of Life: The key to a healthy pregnancy and baby was my rheumatologist’s accurate evaluation of my condition and reassurance that my health was suitable for pregnancy. The patient’s trust that the doctor will make the best decision for her makes it easier to make difficult decisions and accept negativities during the process. At this point, clinical expertise alone is not enough. The physician’s communication, long-term follow-up, and interdisciplinary coordination are all crucial for the patient’s acceptance of the disease, adherence to treatment, and overall adjustment. In addition to the professionalism of my doctors, their coordination, patient communication and the decrease in my daily stress level increased my quality of life during pregnancy and allowed me to have a healthy pregnancy and birth without complications at age 34.

Takeaway:

Effective communication and a trusting doctor–patient relationship improve patient adherence and emotional resilience.

Interdisciplinary coordination is essential, especially in pregnancies complicated by rheumatologic disease.

A personalized approach that considers the patient’s life circumstances enhances treatment success.


Disclosures: T. Turten Kaymaz: None

To cite this abstract in AMA style:

Turten Kaymaz T. My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/my-journey-of-risk-loss-and-hope-the-role-of-multidisciplinary-collaboration-in-managing-pregnancy-with-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/my-journey-of-risk-loss-and-hope-the-role-of-multidisciplinary-collaboration-in-managing-pregnancy-with-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology